Biomarker ImprovementsValidated biomarkers of AD and neurodegeneration, including protein pathology, inflammation, and neurodegeneration, showed directional improvements favoring fosgonimeton.

Drug DevelopmentThe company remains focused on advancing next-gen oral HGF/MET modulator ATH-1105.

Strategic PartnershipsThe company has initiated a strategic review process to explore strategic alternatives, including the potential to secure a strategic partnership for ATH-1105.

Bears Say

Clinical Trial ResultsFosgonimeton failed to meet primary endpoints in the LIFT-AD Phase 2/3 trial and development of the candidate has been discontinued.

Stock PerformanceThe stock traded off approximately 75% after market, significantly underperforming the biotech index which showed no change.

Valuation ConcernsAt the current level, the stock is trading at around 35% of its cash value at the end of August, raising concerns about its valuation.

---

Financials

Annual

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

10.59% Insiders

5.39% Mutual Funds

0.09% Other Institutional Investors

75.93% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Detailed Risk Analysis >

Website Traffic

Sorry, No Data Available

There is no website visitor data available for this stock.

---

ATHA FAQ

What was Athira Pharma, Inc.’s price range in the past 12 months?

Athira Pharma, Inc. lowest stock price was $0.41 and its highest was $4.30 in the past 12 months.

What is Athira Pharma, Inc.’s market cap?

Athira Pharma, Inc.’s market cap is $20.53M.

When is Athira Pharma, Inc.’s upcoming earnings report date?

Athira Pharma, Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 61 days.

How were Athira Pharma, Inc.’s earnings last quarter?

Athira Pharma, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.702 by -$0.048.

Is Athira Pharma, Inc. overvalued?

According to Wall Street analysts Athira Pharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Athira Pharma, Inc. pay dividends?

Athira Pharma, Inc. does not currently pay dividends.

What is Athira Pharma, Inc.’s EPS estimate?

Athira Pharma, Inc.’s EPS estimate is -0.41.

How many shares outstanding does Athira Pharma, Inc. have?

Athira Pharma, Inc. has 38,669,070 shares outstanding.

What happened to Athira Pharma, Inc.’s price movement after its last earnings report?

Athira Pharma, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.702. Following the earnings report the stock price went down -12%.

Which hedge fund is a major shareholder of Athira Pharma, Inc.?

Currently, no hedge funds are holding shares in ATHA

---

Company Description

Athira Pharma, Inc.

Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

---